Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | BMP1 | P13497 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562970 | 0.89 | SLC2A1 (0.43) | SLC2A1TP53LMNATGFBR1GRIN2B | |
| SCHEMBL563638 | 0.83 | BRD4 (0.41) | TGFBR1BRD4KDM4E | |
| SCHEMBL563121 | 0.82 | KDM4E (0.38) | LMNAALDH1A1HTTKDM4E | |
| SCHEMBL563646 | 0.81 | KDM4E (0.39) | ALDH1A1NR1D1BRD4KDM4E | |
| SCHEMBL3339558 | 0.78 | SLC2A1 (0.42) | SLC2A1TP53LMNATGFBR1ALDH1A1 | |
| SCHEMBL4762924 | 0.76 | ALDH1A1 (0.41) | ALDH1A1KDM4E | |
| SCHEMBL4762917 | 0.76 | ALDH1A1 (0.41) | ALDH1A1KDM4E | |
| SCHEMBL3339765 | 0.76 | EGFR (0.46) | TP53LMNAALDH1A1HTTKDM4E | |
| SCHEMBL14797911 | 0.73 | GPR119 (0.48) | TGFBR1GRIN2BNR1D1STSBRD4 | |
| SCHEMBL29269211 | 0.72 | KDM1A (0.37) | SLC2A1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035209-A1 | Hydroxy Substituted 1H-Imidazopyridines and Methods | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20100152230-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | PFIZER INC. | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152230-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | IL4, IL2, IL4I1 | SLC2A1 4811/4885TP53 221/4885LMNA 3107/4885 |
| US-20120035209-A1 | Hydroxy Substituted 1H-Imidazopyridines and Methods | IL2, IL4, IL4I1 | SLC2A1 4808/4885TP53 196/4885LMNA 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.